Case report: tumefactive demyelinating lesions after the second cycle of alemtuzumab in multiple sclerosis; immune cell profile and biomarkers
ObjectiveWe present a case of multiple tumefactive demyelinating lesions (TDLs) emerging 24 months after the second cycle of alemtuzumab treatment.MethodsA woman with relapsing-remitting multiple sclerosis (MS) discontinued fingolimod treatment due to …